Symmetry Breaking: Bispecific Antibodies, the Beginnings, and 50 Years on

Overview

Journal Cancer Immun

Specialties Allergy & Immunology
Oncology

Date 2012 Aug 17

PMID 22896757

Citations 45

Authors

Gert Riethmuller

Affiliations

Soon will be listed here.

Citing Articles

Bispecific FpFs: a versatile tool for preclinical antibody development.

Collins M, Ibeanu N, Grabowska W, Awwad S, Khaw P, Brocchini S RSC Chem Biol. 2024; .

PMID: 39347456 PMC: 11427889. DOI: 10.1039/d4cb00130c.

Developability considerations for bispecific and multispecific antibodies.

Amash A, Volkers G, Farber P, Griffin D, Davison K, Goodman A MAbs. 2024; 16(1):2394229.

PMID: 39189686 PMC: 11352713. DOI: 10.1080/19420862.2024.2394229.

Facile Access to Branched Multispecific Proteins.

Okon A, Yang J, Giancola J, Molina O, Sayers J, Cheah K Bioconjug Chem. 2024; 35(7):954-962.

PMID: 38879814 PMC: 11254548. DOI: 10.1021/acs.bioconjchem.4c00162.

Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future.

Lampe H, Tam L, Hansen A Front Pharmacol. 2024; 15:1399802.

PMID: 38873417 PMC: 11169794. DOI: 10.3389/fphar.2024.1399802.

Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.

Yin N, Li X, Zhang X, Xue S, Cao Y, Niedermann G Signal Transduct Target Ther. 2024; 9(1):126.

PMID: 38773064 PMC: 11109181. DOI: 10.1038/s41392-024-01826-z.

References

Schwartz R . Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 1992; 71(7):1065-8. DOI: 10.1016/s0092-8674(05)80055-8. View

Nisonoff A, RIVERS M . Recombination of a mixture of univalent antibody fragments of different specificity. Arch Biochem Biophys. 1961; 93:460-2. DOI: 10.1016/0003-9861(61)90296-x. View

Milstein C, Cuello A . Hybrid hybridomas and their use in immunohistochemistry. Nature. 1983; 305(5934):537-40. DOI: 10.1038/305537a0. View

Beck A, Wurch T, Bailly C, Corvaia N . Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010; 10(5):345-52. DOI: 10.1038/nri2747. View

Karpovsky B, Titus J, Stephany D, Segal D . Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies. J Exp Med. 1984; 160(6):1686-701. PMC: 2187539. DOI: 10.1084/jem.160.6.1686. View

Weiner L, Clark J, Davey M, Li W, Garcia de Palazzo I, Ring D . Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res. 1995; 55(20):4586-93. View

Hartmann F, Renner C, Jung W, Da Costa L, Tembrink S, Held G . Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res. 2001; 7(7):1873-81. View

Reichert J . Antibody-based therapeutics to watch in 2011. MAbs. 2010; 3(1):76-99. PMC: 3038014. DOI: 10.4161/mabs.3.1.13895. View

Reichert J . Metrics for antibody therapeutics development. MAbs. 2010; 2(6):695-700. PMC: 3011223. DOI: 10.4161/mabs.2.6.13603. View

10.

Fanger M, Segal D, Wunderlich J . Going both ways: bispecific antibodies and targeted cellular cytotoxicity. FASEB J. 1990; 4(11):2846-9. DOI: 10.1096/fasebj.4.11.2199282. View

11.

Topp M, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S . Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011; 29(18):2493-8. DOI: 10.1200/JCO.2010.32.7270. View

12.

Hartmann F, Renner C, Jung W, Deisting C, Juwana M, Eichentopf B . Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood. 1997; 89(6):2042-7. View

13.

Staerz U, Bevan M . Use of anti-receptor antibodies to focus T-cell activity. Immunol Today. 2014; 7(7-8):241-5. DOI: 10.1016/0167-5699(86)90112-X. View

14.

Fudenberg H, Drews G, Nisonoff A . SEROLOGIC DEMONSTRATION OF DUAL SPECIFICITY OF RABBIT BIVALENT HYBRID ANTIBODY. J Exp Med. 1964; 119:151-66. PMC: 2137801. DOI: 10.1084/jem.119.1.151. View

15.

Jung G, Ledbetter J, MULLER-EBERHARD H . Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc Natl Acad Sci U S A. 1987; 84(13):4611-5. PMC: 305140. DOI: 10.1073/pnas.84.13.4611. View

16.

Huang R, Jalil J, Economou J, Chmielowski B, Koya R, Mok S . CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011; 17(12):4101-9. PMC: 3117971. DOI: 10.1158/1078-0432.CCR-11-0407. View

17.

Masopust D, Vezys V, Marzo A, Lefrancois L . Preferential localization of effector memory cells in nonlymphoid tissue. Science. 2001; 291(5512):2413-7. DOI: 10.1126/science.1058867. View

18.

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

19.

Renner C, Pfreundschuh M . Tumor therapy by immune recruitment with bispecific antibodies. Immunol Rev. 1995; 145:179-209. DOI: 10.1111/j.1600-065x.1995.tb00082.x. View

20.

Davis J, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo K . SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel. 2010; 23(4):195-202. DOI: 10.1093/protein/gzp094. View